Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5260291 | MERCK SHARP DOHME | Tetrazine derivatives |
Aug, 2013
(10 years ago) | |
US5260291 (Pediatric) | MERCK SHARP DOHME | Tetrazine derivatives |
Feb, 2014
(10 years ago) | |
US7786118 | MERCK SHARP DOHME | Pharmaceutical formulations of antineoplastic agents |
Feb, 2023
(1 year, 2 months ago) | |
US8623868 | MERCK SHARP DOHME | Processes of making and using pharmaceutical formulations of antineoplastic agents |
Feb, 2023
(1 year, 2 months ago) | |
US6987108 | MERCK SHARP DOHME | Pharmaceutical formulations of antineoplastic agents and processes of making and using the same |
Sep, 2023
(7 months ago) |
Temodar is owned by Merck Sharp Dohme.
Temodar contains Temozolomide.
Temodar has a total of 5 drug patents out of which 5 drug patents have expired.
Expired drug patents of Temodar are:
Temodar was authorised for market use on 27 February, 2009.
Temodar is available in capsule;oral, powder;intravenous dosage forms.
Temodar can be used as treatment of malignant neoplasm.
The generics of Temodar are possible to be released after 08 September, 2023.
Drugs and Companies using TEMOZOLOMIDE ingredient
Market Authorisation Date: 27 February, 2009
Treatment: Treatment of malignant neoplasm
Dosage: POWDER;INTRAVENOUS; CAPSULE;ORAL